Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flumatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 18/20 | 1.00 |
| ▸ | BCR | P11274 | 15/20 | 1.00 |
| ▸ | KIT | P10721 | 5/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 4/20 | 1.00 |
| ▸ | LYN | P07948 | 7/20 | 0.85 |
| ▸ | CSF1R | P07333 | 3/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.64 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | SYK | P43405 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | FYN | P06241 | 2/20 | 0.64 |
| ▸ | BRAF | P15056 | 2/20 | 0.64 |
| ▸ | NQO2 | P16083 | 2/20 | 0.64 |
| ▸ | ABL2 | P42684 | 2/20 | 0.64 |
| ▸ | FRK | P42685 | 2/20 | 0.64 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.64 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flumatinib SCHEMBL29384719 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL30087592 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL29410819 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL29573502 | 0.97 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL29572991 | 0.97 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL4889246 | 0.97 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| SCHEMBL3560947 | 0.92 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| SCHEMBL988244 | 0.91 | ABL1 (0.84) | ABL1BCRKITPDGFRBLYN | |
| SCHEMBL4891357 | 0.91 | ABL1 (0.84) | ABL1BCRKITPDGFRBLYN | |
| SCHEMBL4894017 | 0.90 | ABL1 (0.95) | ABL1BCRKITPDGFRBLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114259497-A | Pharmaceutical composition of aminopyrimidine compounds and preparation method thereof | 江苏豪森药业集团有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-107648237-B | Pharmaceutical composition of aminopyrimidine compounds and preparation method thereof | 江苏豪森药业集团有限公司 | 2022-03-04 | — | — | CN | claimed |
| EP-1840122-B1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | SUN PIAOYANG (CN) | 2013-08-28 | — | — | EP | claimed |
| US-8183242-B2 | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof | Sun, Piaoyang (CN) | 2012-05-22 | — | — | US | claimed |
| US-20080312251-A1 | Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2008-12-18 | — | — | US | claimed |
| EP-1840122-A1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | Sun, Piaoyang (CN) | 2007-10-03 | — | — | EP | claimed |
| EP-3700516-B1 | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LTD (VG) | 2024-01-24 | — | — | EP | disclosed |
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2023-11-07 | — | — | US | disclosed |
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2023-11-07 | — | — | US | disclosed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | disclosed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | disclosed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230190769-A1 | E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-22 | — | — | US | disclosed |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | SONIC MASTER LIMITED (VG) | 2020-10-22 | — | — | US | disclosed |
| CN-111763170-A | Preparation method of flumatinib intermediate | 江苏豪森药业集团有限公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-1840122-B1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | SUN PIAOYANG (CN) | 2013-08-28 | — | — | EP | disclosed |
| US-8183242-B2 | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof | Sun, Piaoyang (CN) | 2012-05-22 | — | — | US | disclosed |
| US-20080312251-A1 | Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2008-12-18 | — | — | US | disclosed |
| EP-1840122-A1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | Sun, Piaoyang (CN) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | ABL1 50/4885BCR 119/4885KIT 3101/4885 |
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | MUSK, MERTK, PRKDC | ABL1 77/4885BCR 193/4885KIT 654/4885 |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | MUSK, MERTK, PRKDC | ABL1 77/4885BCR 193/4885KIT 654/4885 |
| US-20080312251-A1 | Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof | DPYD, PKN2, TYMP | ABL1 7/4885BCR 2529/4885KIT 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.